Editas Medicine Announces Third Quarter 2026 Results and Business Updates
Editas Medicine reported Q3 2026 results with a net loss of $23.4 million ($0.15 per share), improved from $25.1 million ($0.28) a year earlier, on collaboration revenue of $10.4 million, up from $7.5 million. The company received HREC approval and completed Australia's CTN process to start the Phase 1/2 Strive study of EDIT-401 in HeFH patients, with patient dosing on track this year, initial safety data in Q1 2027, and topline Part 1 results in 2H 2027. Preclinical data showed ≥90% LDL-C reduction maintained over 10 months in non-human primates.
Key figures
- Revenue
- 10365000
- Guidance
- Initial EDIT-401 safety/tolerability data Q1 2027; topline Strive Part 1 results 2H 2027
- Revenue Yoy
- 37%
- Cash runway
- into the second half of 2028
- Net loss q3
- 23393000
- Ga expense q3
- 13477000
- Rd expense q3
- 21170000
- Ldl c reduction nhp
- ≥90% maintained over 10 months
- Cash and marketable securities
- 190198000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.